CLC bio Continues Success with a 30 Percent Growth in Software Sales and over 500 New Organizations as Customers in 2012

CLC bio Continues Success with a 30 Percent Growth in Software Sales and over 500 New Organizations as Customers in 2012
February 12, 2013

AARHUS, Denmark--(BUSINESS WIRE)--Today, the world's leading bioinformatics software company, CLC bio, is pleased to announce a continued positive development in 2012 with a 30% increase in both software sales and employees, and more than a 30% rise in new organizations as customers.

"In many ways, 2012 featured significant milestones for us as a company. We now have more than 100 employees around the world, which together with our market reach makes us the largest bioinformatics company focusing on next generation sequencing. We also added more than 500 new unique organizations to our customer list, surpassing 2000 in total", states CEO at CLC bio, Thomas Knudsen, and continues, "In September we acquired our first company, Molegro. This was a very positive process and we're looking forward to bringing even more drug discovery software to the market in the future. Last but not least, we're profitable and cash-flow positive for the third year in a row, enabling further growth in the years to come."

Adding another 2.9 million US Dollars to the total income, CLC bio also joined two European Union funded FP7 projects, STATegra and PATHSEEK. In collaboration with some of the leading scientists in Europe, the company will provide their expertise and platform to develop novel ways of analyzing, comparing, and visualizing next generation sequencing data.

"We recently compiled a survey on the general next generation sequencing field, which had over 700 respondents and confirmed several themes that are completely aligned with our strategic focus on the agriculture and medical genomics segments," adds Vice President of Communications at CLC bio, Lasse Görlitz.

CLC bio is a privately owned company, primarily funded by local investors and successfully built without venture capital since January 2005. CLC bio is based in Aarhus, Denmark. CLC bio exports 98% of its software to organizations in countries outside of Denmark, and 50% of the sales are generated in the USA.

About CLC bio


CLC bio
Lasse Görlitz
Vice President of Communications
Direct: +1 (617) 765 0687
E-mail: [email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.